An immunological signature to predict outcome in patients with triple-negative breast cancer with residual disease after neoadjuvant chemotherapy

BACKGROUND: When triple-negative breast cancer (TNBC) patients have residual disease after neoadjuvant chemotherapy (NACT), they have a high risk of metastatic relapse. With immune infiltrate in TNBC being prognostic and predictive of response to treatment, our aim was to develop an immunologic tran...

Descripción completa

Detalles Bibliográficos
Autores principales: Blaye, C., Darbo, É., Debled, M., Brouste, V., Vélasco, V., Pinard, C., Larmonier, N., Pellegrin, I., Tarricone, A., Arnedos, M., Commeny, J., Bonnefoi, H., Larmonier, C., MacGrogan, G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434232/
https://www.ncbi.nlm.nih.gov/pubmed/35759853
http://dx.doi.org/10.1016/j.esmoop.2022.100502

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434232/
https://www.ncbi.nlm.nih.gov/pubmed/35759853
http://dx.doi.org/10.1016/j.esmoop.2022.100502

Ejemplares similares